RxDoctor Payments Data

Richard Holt, MD

Orthopaedic Surgery of the Spine · Louisville, KYNPI 1669455630

Payments from drug & device makers

What this record shows

The money is spread across several categories — royalties or licence payments (57.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 11 manufacturers reported payments, led by Globus Medical at 57.5% of the total. Reporting peaked in 2019 at $2,018 and has fallen 99.3% since, to $13 in 2024. That places this record below the midpoint for orthopaedic surgery of the spine clinicians in KY, where the typical reported total is $61,310.

$2,703in general payments, 2019–2025

Across 42 payments — averaging $64.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Globus Medical$2K
  • Teva Pharmaceuticals USA, Inc.$294
  • Spineology Inc.$197
  • UCB, Inc.$153
  • Sunovion Pharmaceuticals Inc.$114
  • Vanda Pharmaceuticals Inc.$84
  • plus $306 from 5 others

What the payments were for

  • Royalty or licence$1,55457%
  • Food & beverage$1,03938%
  • Education$1114%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,703 in reported general payments places this provider in the 15th percentile of 29 orthopaedic surgery of the spine providers in Kentucky.

See all orthopaedic surgery of the spine providers in Kentucky

Medicare billing

Part B allowed, 2024
$4,682
Medicare patients
41
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BriviactBrivaracetam15$27,036
EliquisApixaban25$16,505
LinzessLinaclotide30$16,487
RybelsusSemaglutide14$14,370
JanumetSitagliptin Phos/Metformin Hcl13$7,716
VascepaIcosapent Ethyl13$6,346
Breo ElliptaFluticasone/Vilanterol13$5,536
Levetiracetam101$5,336
Desmopressin Acetate34$5,275
Divalproex Sodium29$4,057
Oxcarbazepine21$3,214
Lubiprostone13$2,625
Divalproex Sodium ErDivalproex Sodium12$2,582
Carbamazepine36$2,474
Esomeprazole Magnesium46$1,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Briviact$153$27,03615 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 29 orthopaedic surgery of the spine providers in Kentucky.

Other orthopaedic surgery of the spine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →